Tags

Type your tag names separated by a space and hit enter

Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
J Rheumatol. 2009 Sep; 36(9):1917-23.JR

Abstract

OBJECTIVE

To determine serum concentrations of soluble CXCL16 and its clinical associations in patients with systemic sclerosis (SSc).

METHODS

Serum CXCL16 levels from 89 patients with SSc were examined by ELISA. In a retrospective longitudinal study, 68 sera from 28 patients with SSc were analyzed (followup 1.3 to 7.3 yrs).

RESULTS

Serum CXCL16 levels were elevated in patients with SSc compared with healthy controls (n = 42). Patients with diffuse cutaneous SSc (n = 52) had higher levels of CXCL16 than those with limited cutaneous SSc (n = 37). Serum CXCL16 levels correlated positively with the extent of skin sclerosis. In the longitudinal study, CXCL16 levels generally decreased on a parallel with the improvement in skin sclerosis.

CONCLUSION

CXCL16 levels were increased in patients with SSc, and correlated with the extent of skin sclerosis, suggesting that CXCL16 may have a role in the development of skin fibrosis in SSc. Blockade of CXCL16 interaction might be a potential therapeutic target in patients with SSc.

Links

Publisher Full Text

Authors+Show Affiliations

Yanaba K
Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Muroi E
No affiliation info available
Yoshizaki A
No affiliation info available
Hara T
No affiliation info available
Ogawa F
No affiliation info available
Shimizu K
No affiliation info available
Yozaki M
No affiliation info available
Hasegawa M
No affiliation info available
Fujimoto M
No affiliation info available
Takehara K
No affiliation info available
Sato S
No affiliation info available

MeSH

AdolescentAdultAgedCase-Control StudiesChemokine CXCL16Chemokines, CXCChildDermatomyositisFemaleFollow-Up StudiesHumansLongitudinal StudiesLupus Erythematosus, SystemicMaleMiddle AgedReceptors, ScavengerRetrospective StudiesScleroderma, SystemicSclerosisSeverity of Illness IndexSkinYoung Adult

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19605674

Citation

Yanaba, Koichi, et al. "Serum CXCL16 Concentrations Correlate With the Extent of Skin Sclerosis in Patients With Systemic Sclerosis." The Journal of Rheumatology, vol. 36, no. 9, 2009, pp. 1917-23.
Yanaba K, Muroi E, Yoshizaki A, et al. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis. J Rheumatol. 2009;36(9):1917-23.
Yanaba, K., Muroi, E., Yoshizaki, A., Hara, T., Ogawa, F., Shimizu, K., Yozaki, M., Hasegawa, M., Fujimoto, M., Takehara, K., & Sato, S. (2009). Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis. The Journal of Rheumatology, 36(9), 1917-23. https://doi.org/10.3899/jrheum.090108
Yanaba K, et al. Serum CXCL16 Concentrations Correlate With the Extent of Skin Sclerosis in Patients With Systemic Sclerosis. J Rheumatol. 2009;36(9):1917-23. PubMed PMID: 19605674.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis. AU - Yanaba,Koichi, AU - Muroi,Eiji, AU - Yoshizaki,Ayumi, AU - Hara,Toshihide, AU - Ogawa,Fumihide, AU - Shimizu,Kazuhiro, AU - Yozaki,Mariko, AU - Hasegawa,Minoru, AU - Fujimoto,Manabu, AU - Takehara,Kazuhiko, AU - Sato,Shinichi, Y1 - 2009/07/15/ PY - 2009/7/17/entrez PY - 2009/7/17/pubmed PY - 2009/11/17/medline SP - 1917 EP - 23 JF - The Journal of rheumatology JO - J Rheumatol VL - 36 IS - 9 N2 - OBJECTIVE: To determine serum concentrations of soluble CXCL16 and its clinical associations in patients with systemic sclerosis (SSc). METHODS: Serum CXCL16 levels from 89 patients with SSc were examined by ELISA. In a retrospective longitudinal study, 68 sera from 28 patients with SSc were analyzed (followup 1.3 to 7.3 yrs). RESULTS: Serum CXCL16 levels were elevated in patients with SSc compared with healthy controls (n = 42). Patients with diffuse cutaneous SSc (n = 52) had higher levels of CXCL16 than those with limited cutaneous SSc (n = 37). Serum CXCL16 levels correlated positively with the extent of skin sclerosis. In the longitudinal study, CXCL16 levels generally decreased on a parallel with the improvement in skin sclerosis. CONCLUSION: CXCL16 levels were increased in patients with SSc, and correlated with the extent of skin sclerosis, suggesting that CXCL16 may have a role in the development of skin fibrosis in SSc. Blockade of CXCL16 interaction might be a potential therapeutic target in patients with SSc. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/19605674/Serum_CXCL16_concentrations_correlate_with_the_extent_of_skin_sclerosis_in_patients_with_systemic_sclerosis_ L2 - http://www.jrheum.org/cgi/pmidlookup?view=long&pmid=19605674 DB - PRIME DP - Unbound Medicine ER -